In addition, Kripa et al. reported that both higher VAT and higher SMA index were significantly associated with improved PFS (HR = 0.476, p = 0.008; HR = 0.687, p < 0.001), highlighting sarcopenia as a negative prognostic factor in HR+/HER2− MBC treated with CDK4/6i [40]. Here, CDK4 is linked to sarcopenia.